These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 18167137)
1. Effect of the resistin -420C > G polymorphism on cardiovascular disease and mortality. Hoffmann MM; Pilz S; Weihrauch G; Seelhorst U; Wellnitz B; Winkelmann BR; Boehm BO; März W Clin Endocrinol (Oxf); 2008 Aug; 69(2):344-5. PubMed ID: 18167137 [No Abstract] [Full Text] [Related]
2. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. Norata GD; Ongari M; Garlaschelli K; Tibolla G; Grigore L; Raselli S; Vettoretti S; Baragetti I; Noto D; Cefalù AB; Buccianti G; Averna M; Catapano AL J Intern Med; 2007 Jul; 262(1):104-12. PubMed ID: 17598818 [TBL] [Abstract][Full Text] [Related]
3. Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C > G genotype. Wågsater D; Mumtaz M; Lofgren S; Hugander A; Dimberg J Cancer Invest; 2008 Dec; 26(10):1008-14. PubMed ID: 18798067 [TBL] [Abstract][Full Text] [Related]
4. Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors. Ukkola O; Kunnari A; Kesäniemi YA Regul Pept; 2008 Aug; 149(1-3):56-9. PubMed ID: 18440081 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular mortality in high-risk patients and T-786C polymorphism in promoter region of the endothelial nitric oxide synthase gene. Tanus-Santos JE; Casella-Filho A J Am Coll Cardiol; 2007 Mar; 49(11):1225-6; author reply 1226-7. PubMed ID: 17367669 [No Abstract] [Full Text] [Related]
6. Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases. Motawi TM; Shaker OG; El-Sawalhi MM; Abdel-Nasser ZM Genome; 2014 May; 57(5):259-66. PubMed ID: 25120107 [TBL] [Abstract][Full Text] [Related]
7. Loxin polymorphism is associated with increased resistin levels and with oxidative status. Gambino R; Bo S; Musso G; Pagano G; Cassader M Clin Biochem; 2011 Aug; 44(12):1015-7. PubMed ID: 21679701 [TBL] [Abstract][Full Text] [Related]
8. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Aker S; Bantis C; Reis P; Kuhr N; Schwandt C; Grabensee B; Heering P; Ivens K Nephrol Dial Transplant; 2009 Sep; 24(9):2847-51. PubMed ID: 19349293 [TBL] [Abstract][Full Text] [Related]
9. [Role of resistin in insulin resistance]. Onuma H; Osawa H; Makino H Rinsho Byori; 2008 Aug; 56(8):698-704. PubMed ID: 18800626 [TBL] [Abstract][Full Text] [Related]
10. Analysis of genetic variations in the resistin gene shows no associations with obesity in women. Beckers S; Peeters AV; Freitas Fd; Mertens IL; Hendrickx JJ; Van Gaal LF; Van Hul W Obesity (Silver Spring); 2008 Apr; 16(4):905-7. PubMed ID: 18239575 [TBL] [Abstract][Full Text] [Related]
11. Genetic variants of resistin and its plasma levels: Association with obesity and dyslipidemia related to type 2 diabetes susceptibility. Rathwa N; Patel R; Palit SP; Ramachandran AV; Begum R Genomics; 2019 Jul; 111(4):980-985. PubMed ID: 29969661 [TBL] [Abstract][Full Text] [Related]
12. Are promoter polymorphisms of interleukin 6 ready to be applied in genetic markers of cardiovascular diseases? Iwamoto S Hypertens Res; 2007 Jul; 30(7):575-6. PubMed ID: 17785923 [No Abstract] [Full Text] [Related]
13. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Tsukahara T; Nakashima E; Watarai A; Hamada Y; Naruse K; Kamiya H; Nakamura N; Kato N; Hamajima N; Sekido Y; Niwa T; Tomita M; Oiso Y; Nakamura J Diabetes Res Clin Pract; 2009 May; 84(2):179-86. PubMed ID: 19269054 [TBL] [Abstract][Full Text] [Related]
14. A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. Zhang D; Ma J; Brismar K; Efendic S; Gu HF J Diabetes Complications; 2009; 23(4):265-72. PubMed ID: 18599322 [TBL] [Abstract][Full Text] [Related]
15. Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients. Buraczynska M; Ksiazek P; Zukowski P; Benedyk-Lorens E; Orlowska-Kowalik G Clin Immunol; 2009 Aug; 132(2):285-90. PubMed ID: 19428307 [TBL] [Abstract][Full Text] [Related]
16. CDH1 C-160A promoter polymorphism and gastric cancer risk. Corso G; Berardi A; Marrelli D; Pedrazzani C; Garosi L; Pinto E; Roviello F Eur J Cancer Prev; 2009 Feb; 18(1):46-9. PubMed ID: 19077564 [TBL] [Abstract][Full Text] [Related]
18. Investigation of resistin 420 and 62 gene polymorphism in patients with endometrial cancer. Ozgor BY; Iyibozkurt C; Bastu E; Berkman S; Yalcın O; Cakmakoglu B; Saygılı H Taiwan J Obstet Gynecol; 2019 Jan; 58(1):164-167. PubMed ID: 30638473 [TBL] [Abstract][Full Text] [Related]
19. Lack of association between a common polymorphism near the INSIG2 gene and BMI, myocardial infarction, and cardiovascular risk factors. Wiedmann S; Neureuther K; Stark K; Reinhard W; Kallmünzer B; Baessler A; Fischer M; Linsel-Nitschke P; Erdmann J; Schunkert H; Hengstenberg C Obesity (Silver Spring); 2009 Jul; 17(7):1390-5. PubMed ID: 19197259 [TBL] [Abstract][Full Text] [Related]
20. Association between tumor necrosis factor-alpha gene promoter polymorphism at position -308 and acne in Turkish patients. Baz K; Emin Erdal M; Yazici AC; Söylemez F; Güvenç U; Taşdelen B; Ikizoğlu G Arch Dermatol Res; 2008 Aug; 300(7):371-6. PubMed ID: 18615253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]